Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer.
Saved in:
| Title: | Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. |
|---|---|
| Authors: | Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Astles PC; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Diène C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Crafter C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hock A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jones T; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Moreau K; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Packer MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Pike A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shaw J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K. |
| Source: | Journal of medicinal chemistry [J Med Chem] 2024 Jul 25; Vol. 67 (14), pp. 11732-11750. Date of Electronic Publication: 2024 Jul 11. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
